http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113637745-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-686 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-686 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2020-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113637745-B |
| titleOfInvention | Methylation molecular marker or its combination and application for detecting benign and malignant pulmonary nodules |
| abstract | The present invention provides DNA methylation molecular markers for detecting benign and malignant pulmonary nodules. The DNA methylation molecular markers are selected from the sequences shown in SEQ ID NO.1 to SEQ ID NO.21 or all of them. Any one of at least 55% of the continuous fragments or a combination of two or more; or at least 55% of the complete complementary sequence selected from the sequence shown in SEQ ID NO.1 to SEQ ID NO.21 or its full length Any one or a combination of two or more of the consecutive segments. Especially among them, SEQ ID NO.8 has higher specificity for detecting benign and malignant pulmonary nodules. The present invention also provides a detection kit and a detection method for the DNA methylation molecular marker. The DNA methylation molecular markers are highly related to lung cancer, especially when used in combination, can further improve the sensitivity and specificity of detecting benign and malignant pulmonary nodules, increase the detection rate of malignant pulmonary nodules, and reduce the detection rate. false positive rate. The primers and probes in the kit overcome the shortcoming of mutual interference of a plurality of primers and probes during multiplex PCR amplification and detection, and the quantitative performance is equivalent to that of a single region. |
| priorityDate | 2020-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 73.